MTOR and neoplasm: These findings were confirmed in nude mice injected subcutaneously with HCT116 cells, where larotrectinib treatment reduced tumor volumes and weight, inducing AMPK phosphorylation with suppression of mTOR, as well as causing LC3I/II conversion.